Dynamic Technology Lab Private Ltd Takes Position in BeiGene, Ltd. (NASDAQ:BGNE)

Dynamic Technology Lab Private Ltd acquired a new stake in BeiGene, Ltd. (NASDAQ:BGNEFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,190 shares of the company’s stock, valued at approximately $215,000.

Other institutional investors and hedge funds have also modified their holdings of the company. BNP Paribas Financial Markets lifted its holdings in shares of BeiGene by 7,724.1% in the 4th quarter. BNP Paribas Financial Markets now owns 59,307 shares of the company’s stock valued at $10,697,000 after buying an additional 58,549 shares during the period. Wellington Management Group LLP increased its stake in shares of BeiGene by 57.4% in the 3rd quarter. Wellington Management Group LLP now owns 55,478 shares of the company’s stock valued at $9,979,000 after purchasing an additional 20,239 shares in the last quarter. abrdn plc increased its stake in shares of BeiGene by 1,346.8% in the 4th quarter. abrdn plc now owns 21,138 shares of the company’s stock valued at $3,812,000 after purchasing an additional 19,677 shares in the last quarter. FMR LLC increased its stake in shares of BeiGene by 3.0% in the 3rd quarter. FMR LLC now owns 2,352,730 shares of the company’s stock valued at $423,186,000 after purchasing an additional 69,297 shares in the last quarter. Finally, M&G Investment Management Ltd. increased its stake in shares of BeiGene by 4.4% in the 4th quarter. M&G Investment Management Ltd. now owns 173,266 shares of the company’s stock valued at $31,188,000 after purchasing an additional 7,325 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on BGNE shares. JPMorgan Chase & Co. lifted their price target on BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a research note on Tuesday, March 19th. Bank of America cut their price objective on BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a research note on Monday, April 8th. Guggenheim cut their price objective on BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. TD Cowen boosted their price objective on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Finally, Sanford C. Bernstein cut their price objective on BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research note on Wednesday, March 27th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, BeiGene currently has a consensus rating of “Moderate Buy” and an average price target of $251.93.

Get Our Latest Analysis on BeiGene

BeiGene Trading Up 0.3 %

BGNE opened at $153.11 on Wednesday. BeiGene, Ltd. has a one year low of $126.97 and a one year high of $241.50. The stock has a market capitalization of $14.65 billion, a PE ratio of -20.23 and a beta of 0.63. The business’s 50 day moving average price is $154.25 and its 200 day moving average price is $164.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.84 and a current ratio of 2.08.

BeiGene (NASDAQ:BGNEGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($2.41) EPS for the quarter, topping analysts’ consensus estimates of ($3.07) by $0.66. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. The company had revenue of $751.70 million for the quarter, compared to analysts’ expectations of $670.09 million. During the same period in the prior year, the firm earned ($3.34) earnings per share. The firm’s revenue was up 67.9% compared to the same quarter last year. As a group, equities research analysts expect that BeiGene, Ltd. will post -8.2 EPS for the current year.

Insider Activity

In other news, CFO Julia Aijun Wang sold 397 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CFO Julia Aijun Wang sold 397 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John Oyler sold 26,716 shares of the stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total value of $3,977,745.24. Following the completion of the sale, the chief executive officer now owns 12,084 shares in the company, valued at $1,799,186.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,781 shares of company stock worth $10,222,381. Corporate insiders own 7.43% of the company’s stock.

BeiGene Company Profile

(Free Report)

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.

Recommended Stories

Want to see what other hedge funds are holding BGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeiGene, Ltd. (NASDAQ:BGNEFree Report).

Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.